Role of Surgery Following Induction Therapy for Stage III Non-Small Cell Lung Cancer
Role of Surgery Following Induction Therapy for Stage III Non-Small Cell Lung Cancer
复制标题
DOI：
10.1016/j.soc.2011.07.006
复制
发表时间：
2011-10-01
影响因子：
1.9
通讯作者：
Krasna, Mark J.
中科院分区：
文献类型：
--
作者：
Daly, Benedict D. T.;Cerfolio, Robert J.;Krasna, Mark J.
在过去的30年中，IIIA期非小细胞肺癌（NSCLC）的新辅助治疗以及IIIB期疾病的手术切除显著改善了III期NSCLC患者以及局部浸润性肿瘤患者的总体治疗结果。不同的化疗方案已被使用，虽然在大多数研究中，一些药物的组合，包括顺铂是标准的。放疗作为诱导方案的一部分似乎提供了更高的切除率和完全切除率，更高剂量的放疗与更好的淋巴结降级相关。对于持续性N2病变患者的切除术和诱导治疗后的全肺切除术仍存在争议。对于持续性N2病变患者的切除术和诱导治疗后的全肺切除术仍存在争议。
Over the last 30 years neoadjuvant treatment of stage IIIA non-small cell lung cancer (NSCLC) followed by surgical resection for stage IIIB disease has significantly improved the overall results of treatment for patients with stage III NSCLC as well as for those with locally invasive tumors. Different chemotherapy regimens have been used, although in most studies some combination of drugs that include cisplatin is the standard. Radiation when given as part of the induction protocol appears to offer a higher rate of resection and complete resection, and higher doses of radiation are associated with better nodal downstaging. Resection in patients with persistent N2 disease and pneumonectomy following induction therapy remain controversial. Resection in patients with persistent N2 disease and pneumonectomy following induction therapy remain controversial.